Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership

Proprietary Synthetic Polynucleotide Platform Accelerates Non-Viral, Footprint-Free Induced Pluripotent Stem Cell Generation Amid Surging Commercialization of iPSC Therapies in JapanSEATTLE, June 16, ...
News Medical

New directions in cell therapy: iPSC platforms and in vivo reprogramming

Induced pluripotent stem cells (iPSCs) are derived from adult cells, such as skin or blood cells, which have been “reprogrammed” back to a stem-cell-like state. This transformation grants them the ...
News Medical

iXCells Biotechnologies reaches iPSC line delivery milestone in collaboration with global biotechnology company

iXCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent ...
Morningstar

Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies

Strategic partnership integrates Pluristyx's clinical-grade iPSC platform into Made Scientific's CDMO services, giving developers a single-source path from cell line to commercial supply. PRINCETON, N ...

Sparkling Sciences Obtains International INCI Certification for iPSC Exosome

Sparkling Sciences Co., Ltd., under TOMO YUME Group, announced it has obtained international INCI certification for iPSC Exosome and completed Kyoto University's patent licensing agreement. INCI Name: ...
technologynetworks

Reprogramming Human Fibroblasts Into Human iPSCs

Human-induced pluripotent stem cells (hiPSCs) can differentiate into various tissues, an invaluable characteristic for personalized regenerative medicine, basic and translational research, and drug ...